Latest renewal allows for up to $5 million per year over five years, and will help M-CERSI further advance its mission to promote the development of new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of FDA-regulated products.

Dr. James Polli’s extraordinary accomplishments in the field of regulatory science make him a UMB Champion of Excellence.

Third-year student pharmacists take the gold for their proposal to develop a transparent tracking system for emerging CAR T-cell gene therapies.

Researchers discuss how to leverage a variety of dissolution and translational modeling strategies to ensure patients continue to have access to safe, effective medications.

First-ever undergraduate competitor takes the gold for project to develop a universal labeling system for hazardous drugs.

Fourth annual M-CERSI “America’s Got Regulatory Science Talent” competition awards third-year student pharmacists first prize for novel solution to improve FDA’s post-marketing surveillance program.

New grants and contracts from a multitude of non-profit and government organizations, as well as the private sector, help the School of Pharmacy achieve the highest funding increase among all professional and graduate schools at the University of Maryland, Baltimore.

More than 500 researchers from academia, government, and industry gather to gain perspective on biomarker development and the application of biomarkers in preclinical and clinical research.

Collaborative study helps validate effectiveness of FDA’s bioequivalence standard, showing no significant differences between major brand name and generic medication used to treat patients with epilepsy.

Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).